248 patients with chronic viral hepatitis B liver fibrosis were enrolled in this 52-week study, and randomized into hydronidone or placebo group. Each group has 124 subjects. Both groups were treated with entecavir antiviral basic therapy.
This study was a randomized, double-blind, placebo-controlled, entecavir basic treatment, multicentre clinical study.~The main objective of this study was to confirm the efficacy and safety of hydronidone in the treatment of chronic hepatitis B liver fibrosis.